个体化顺势疗法药物治疗一期原发性高血压:一项双盲、随机、安慰剂对照的试点试验。

IF 2.3 4区 医学 Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE
Satarupa Sadhukhan, Subhas Singh, James Michael, Pankhuri Misra, Maneet Parewa, Arunava Nath, Nitin Magotra, Nivedita Kundu, Anamika Basu, Sk Swaif Ali, Munmun Koley, Subhranil Saha
{"title":"个体化顺势疗法药物治疗一期原发性高血压:一项双盲、随机、安慰剂对照的试点试验。","authors":"Satarupa Sadhukhan,&nbsp;Subhas Singh,&nbsp;James Michael,&nbsp;Pankhuri Misra,&nbsp;Maneet Parewa,&nbsp;Arunava Nath,&nbsp;Nitin Magotra,&nbsp;Nivedita Kundu,&nbsp;Anamika Basu,&nbsp;Sk Swaif Ali,&nbsp;Munmun Koley,&nbsp;Subhranil Saha","doi":"10.1089/acm.2020.0222","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Objective:</i></b> The present study assessed the feasibility of a definitive placebo-controlled trial for evaluating individualized homeopathy (IH) in stage I hypertension (HTN). <b><i>Design:</i></b> Double-blind, randomized (IH: 34, placebo: 34), placebo-controlled, parallel arms, pilot trial. <b><i>Settings/Location:</i></b> National Institute of Homoeopathy, India. <b><i>Subjects:</i></b> Patients suffering from stage I HTN. <b><i>Interventions:</i></b> IH and identical-looking placebo. <b><i>Outcome measures:</i></b> Feasibility issues, blood pressure (BP) and Measure Yourself Medical Outcome Profile-2 (MYMOP-2) were assessed for 6 months. <b><i>Results:</i></b> The recruitment and retention rates were 44.4% and 85.3%, respectively. Group differences were seemingly higher in the IH group than in the placebo group. <b><i>Conclusions:</i></b> Despite challenges in recruitment, an adequately powered efficacy trial appears feasible in the future.</p>","PeriodicalId":14944,"journal":{"name":"Journal of alternative and complementary medicine","volume":"27 6","pages":"515-521"},"PeriodicalIF":2.3000,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Individualized Homeopathic Medicines in Stage I Essential Hypertension: A Double-Blind, Randomized, Placebo-Controlled Pilot Trial.\",\"authors\":\"Satarupa Sadhukhan,&nbsp;Subhas Singh,&nbsp;James Michael,&nbsp;Pankhuri Misra,&nbsp;Maneet Parewa,&nbsp;Arunava Nath,&nbsp;Nitin Magotra,&nbsp;Nivedita Kundu,&nbsp;Anamika Basu,&nbsp;Sk Swaif Ali,&nbsp;Munmun Koley,&nbsp;Subhranil Saha\",\"doi\":\"10.1089/acm.2020.0222\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b><i>Objective:</i></b> The present study assessed the feasibility of a definitive placebo-controlled trial for evaluating individualized homeopathy (IH) in stage I hypertension (HTN). <b><i>Design:</i></b> Double-blind, randomized (IH: 34, placebo: 34), placebo-controlled, parallel arms, pilot trial. <b><i>Settings/Location:</i></b> National Institute of Homoeopathy, India. <b><i>Subjects:</i></b> Patients suffering from stage I HTN. <b><i>Interventions:</i></b> IH and identical-looking placebo. <b><i>Outcome measures:</i></b> Feasibility issues, blood pressure (BP) and Measure Yourself Medical Outcome Profile-2 (MYMOP-2) were assessed for 6 months. <b><i>Results:</i></b> The recruitment and retention rates were 44.4% and 85.3%, respectively. Group differences were seemingly higher in the IH group than in the placebo group. <b><i>Conclusions:</i></b> Despite challenges in recruitment, an adequately powered efficacy trial appears feasible in the future.</p>\",\"PeriodicalId\":14944,\"journal\":{\"name\":\"Journal of alternative and complementary medicine\",\"volume\":\"27 6\",\"pages\":\"515-521\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2021-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of alternative and complementary medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/acm.2020.0222\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/3/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"INTEGRATIVE & COMPLEMENTARY MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of alternative and complementary medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/acm.2020.0222","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/3/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 3

摘要

目的:本研究评估了一项明确的安慰剂对照试验评估I期高血压(HTN)个体化顺势疗法(IH)的可行性。设计:双盲、随机(对照组:34例,安慰剂组:34例)、安慰剂对照、平行组、先导试验。设置/地点:印度国家顺势疗法研究所。研究对象:I期HTN患者。干预措施:IH和外观相同的安慰剂。结果测量:评估可行性问题、血压(BP)和自我测量医疗结果概况-2 (MYMOP-2),为期6个月。结果:招聘率为44.4%,留用率为85.3%。IH组的组间差异似乎高于安慰剂组。结论:尽管在招募方面存在挑战,但未来一项足够有力的疗效试验似乎是可行的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Individualized Homeopathic Medicines in Stage I Essential Hypertension: A Double-Blind, Randomized, Placebo-Controlled Pilot Trial.

Objective: The present study assessed the feasibility of a definitive placebo-controlled trial for evaluating individualized homeopathy (IH) in stage I hypertension (HTN). Design: Double-blind, randomized (IH: 34, placebo: 34), placebo-controlled, parallel arms, pilot trial. Settings/Location: National Institute of Homoeopathy, India. Subjects: Patients suffering from stage I HTN. Interventions: IH and identical-looking placebo. Outcome measures: Feasibility issues, blood pressure (BP) and Measure Yourself Medical Outcome Profile-2 (MYMOP-2) were assessed for 6 months. Results: The recruitment and retention rates were 44.4% and 85.3%, respectively. Group differences were seemingly higher in the IH group than in the placebo group. Conclusions: Despite challenges in recruitment, an adequately powered efficacy trial appears feasible in the future.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of alternative and complementary medicine
Journal of alternative and complementary medicine 医学-全科医学与补充医学
CiteScore
4.00
自引率
0.00%
发文量
0
审稿时长
3 months
期刊介绍: The Journal of Alternative and Complementary Medicine: Paradigm, Practice, and Policy Advancing Integrative Health is the leading peer-reviewed journal providing scientific research for the evaluation and integration of complementary and alternative medicine into mainstream medical practice. The Journal delivers original research that directly impacts patient care therapies, protocols, and strategies, ultimately improving the quality of healing. The Journal of Alternative and Complementary Medicine coverage includes: -Botanical Medicine -Acupuncture and Traditional Chinese Medicine -Other Traditional Medicine Practices -Mind-Body Medicine -Nutrition and Dietary Supplements -Integrative Health / Medicine -Yoga -Ayurveda -Naturopathy -Creative Arts Therapies -Integrative Whole Systems / Whole Practices -Homeopathy -Tai Chi -Qi Gong -Massage Therapy -Subtle Energies and Energy Medicine -Integrative Cost Studies / Comparative Effectiveness -Neurostimulation -Integrative Biophysics
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信